tradingkey.logo
tradingkey.logo
Search

Harvard Bioscience Inc

HBIO
Add to Watchlist
6.050USD
-0.100-1.63%
Close 07/01, 16:00ETQuotes delayed by 15 min
27.29MMarket Cap
LossP/E TTM

More Details of Harvard Bioscience Inc Company

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Harvard Bioscience Inc Info

Ticker SymbolHBIO
Company nameHarvard Bioscience Inc
IPO dateOct 21, 2013
CEODuke (John D)
Number of employees330
Security typeOrdinary Share
Fiscal year-endOct 21
Address84 October Hill Rd
CityHOLLISTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01746-1371
Phone15088938999
Websitehttps://www.harvardbioscience.com/
Ticker SymbolHBIO
IPO dateOct 21, 2013
CEODuke (John D)

Company Executives of Harvard Bioscience Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

FAQs

Who are the top five shareholders of Harvard Bioscience Inc?

The top five shareholders of Harvard Bioscience Inc are: Ms. Katherine Anne Eade, J.D.

How many institutions hold shares of Harvard Bioscience Inc (HBIO)?

As of 2026Q1, 201 institutions hold shares of Harvard Bioscience Inc, with a combined market value of approximately 2.44M, accounting for 54.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -447956.00.

What is the biggest source of revenue for Harvard Bioscience Inc?

In 2026Q1, the Instruments, equipment, software and accessories business generated the highest revenue for Harvard Bioscience Inc, amounting to 78.26M and accounting for 90.42% of total revenue.